





Objectives Intro to Corpus Christi Cancer Center Contouring Normal tissue dosimetric guidelines 18 patient case study specifics 3D comparisons 1 Retrospective replan VMAT Discussion/Closing


















Demographics


- ▶ 250-275 New patients per year
 - ▶ 30%-35% breasts
- ▶ 20%-25% include lymph nodes
































Contouring

- ▶ At patient # 5, I began drawing in the esophagus and avoidance structures. Spoiler alert Patient #5 is the one I replanned.
- ▶ Monaco optimizes very well without avoidance structures.
- ► Avoidance structures most often drawn. Ipsilateral lung, and esophagus
- ▶ Started using "tuning" structures to control low doses primarily on the contralateral side

Normal Tissue Dosimetric Guidelines



Normal Tissue Dosimetric Guidelines

Quantec

- ▶ Ipsilateral Lung V20 <30% Dmean <20Gy
- ► Heart V30 <45% Dmean <26Gy
- ► Esophagus V50 <40% Dmean < 34 Gy

Normal Tissue Dosimetric Guidelines

RTOG 1304 Amendment 3

Ipsilateral Lung V20 < 15-35 Gy Range of acceptable variant

Heart V25 < 10% Dmean < 4 Gy

</=5 Gy Acceptable variant



Normal Tissue Dosimetric Guidelines

► Esophagus V30 </= 10% Dmean < 12Gy

Normal Tissue Dosimetric Guidelines

Target Coverage

- ▶ Breast/ Chest Wall 90% 95%>/= 50 Gy
- ► At Risk Nodes 90%-95% >/= 50 Gy
- ► IMN 80%-90% >/= 50 Gy



Normal Tissue Dosimetric Guidelines

- ► Exposure of the lungs in breast cancer radiotherapy: A systemic review of lung doses published 2010-2015
 - Marianne C. Aznar, Frances K. Duane, Sarah C. Darby, Zhe Wang, Carolyn W. Taylor
- ▶ The average mean ipsilateral lung dose with internal mammary chain irradiation was 14 Gy.
- Published 2017 Radiotherapy and Oncology

Normal Tissue Dosimetric Guidelines

- ▶ Post mastectomy intensity modulation radiated therapy of chest wall and regional nodes
- ▶ Retrospective analysis of the performance and complications up to 5 years
- ▶ Qiong Wang Phd, Wuyun Jie MD, Zhiwen Liang MD, Hongge Wu PhD, Jing Cheng PhD

Heart Doses V20 8.28% +/- 6.55%

Dmean (Gy) 6.99 +/- 3.01

- · 200 patients in the study, only 101 received IMN irradiation
- 3 patients in this study were noted to have acute radiation esophagitis

Published 2017 Medicine



References

- ▶ Aznar MC, Duane FK, Darby SC, Wang Z, Taylor CW. Exposure of the lungs in breast cancer radiotherapy: A systematic review of lung doses published 2010-2015. Radiotherapy and Oncology 126 (2018) 148-154.
- ▶ Wang Q, Jie W, Zhiwen L, Wu H, Cheng J. Postmastectomy intensity modulation radiated therapy of chest wall and regional nodes. Retrospective analysis of the performance and complications up for 5 years. Medicine (2017) 96:39.
- White J, Tai A, Arthur D, Buckholz T, MacDonald S, Marks L, Pierce L, Recht A, Rabinovitch R, Taghian A, Vicini F, Woodward W, Li A. Breast Cancer Atlas for Radiation Therapy Planning: Consensus Definitions. Radiation Therapy Oncology Group website. https://www.rtog.org/CoreLab/ContouringAtlases/





18 Case Specifics


- Laterality Breakdown: 5 Intact Right Breast, 4 Intact Left Breast, 5 Right Chest wall, 4 Left Chest wall. Total 18 patients
- ► Age range: 31-74 years
- ► Technique: DMLC 7-9 fields
- ► Energy: 6X and/or 10X
- ▶ 1 to 1.5 cm fluence was added to achieve "flash"
- ▶ We do DIBH on left sided breast or chest wall
- ▶ All scars and drain sites are included
- ▶ All patients received a tumor bed boost/scar boost of 10 Gy


18 Case Specifics

Why did I do this?

- ▶ The physician put in his intent prescription include IMN "if possible."
- ▶ 3 of the early patients had PET+ IMN disease before chemo, and 1 had PET+ disease in the IMN upper mediastinum and supra clavicular nodes after chemo
- ▶ When compared, 3D mono-isocentric techniques were essentially inferior in basically every measure. Junction and transition areas between the nodes areas and the Breast/Chest wall volumes are particularly problematic with 3D.
- Once you start doing them with volumes it is hard to be satisfied with the results you get with 3D plans
































Target Coverage Patient # 17 Right Intact Breast Right Breast 99.6% @ 50Gy At Risk Nodes 95.7% @ 50Gy ► IMN Dmean 50.4Gy













































Retrospective Replan

Retrospective Replan


- Patient # 5 Right Intact Breast
- ▶ Was the only plan of the 18 that I did not 100% meet all of my dose goals
- ▶ IMN Dmean in the original plan was 38.6 Gy
- ▶ R Lung V20 went from 29.9% to 24.7%
- This patient was also re-planned to reduce esophageal dose at fraction #8 of 25
- ▶ In hind sight the optimization process was flawed from the beginning
- ► From this patient the esophagus/trachea is contoured and optimized to minimize pharyngitis










































Considerations, questions and observations From the community perspective this area is very open to interpretations. It is difficult to discern from the literature whether you are comparing apples, oranges or bananas There are questions on contours, set ups positioning, immobilization DMLC/VMAT vs 3D DIBH for the left side I am right in the learning curve of the next evolution.



Discussion/Closing

▶ After compiling this data, and based on our results we continue to abide by the OAR and Target levels in RTOG 1304.

Dose Goals

- ▶ Breast/chest wall Target 90%-95% >/= 50 Gy
- ▶ Ipsilateral Lung V20 </= 15-35%
- ► Heart V25 </= 10% Dmean <4-5 Gy

Discussion/Closing

- ▶ All in all I feel really good about what we did for this group of patients.
- ▶ I am interested in seeing if I can use VMAT in all cases.
- In the words of Oprah, "when you know better, do better."
- ▶ I am very interested in knowing what other people are doing, and exchanging experiences and ideas.
- ▶ Special thanks to: Gerard J Voorhees, MD

Curtis Volgamore, MS, DABR



